Correlation Engine 2.0
Clear Search sequence regions

Sizes of these terms reflect their relevance to your search.

Acetyl-CoA carboxylase (ACC) is one of the more promising therapeutic targets for non-alcoholic steatohepatitis (NASH), but current ACC inhibitors already tested in clinical trials also exert the unwanted adverse side effect of hypertriglyceridemia. In two recent studies by Calle et al. in Nature Medicine and Zhang et al. in Science Translational Medicine, new strategies for ACC targeting were explored for NASH therapy that successfully resolved the adverse effect of hyperlipidemia while maintaining potent anti-NASH efficacy. These findings bring encouraging new momentum to the clinical application of ACC inhibition for NASH therapy. Copyright © 2022 Elsevier Inc. All rights reserved.


Huijie Bian, Ye-Mao Liu, Zhi-Nan Chen. New avenues for NASH therapy by targeting ACC. Cell metabolism. 2022 Feb 01;34(2):191-193

Expand section icon Mesh Tags

Expand section icon Substances

PMID: 35108509

View Full Text